Dianthus Therapeutics, Inc. /DE/ (DNTH) is a publicly traded company in the Unknown sector. Across all available filings, 10 corporate insiders have executed 30 transactions totaling $10.4M, demonstrating a bearish sentiment with -$7.5M in net insider flow. The most recent transaction on Feb 3, 2026 involved a transaction of 355,000 shares valued at $0.
No significant insider buying has been recorded for DNTH in the recent period.
No significant insider selling has been recorded for DNTH in the recent period.
Based on recent SEC filings, insider sentiment for DNTH is bearish with an Insider Alignment Score of 14/100 and a net flow of -$7.5M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Dianthus Therapeutics, Inc. /DE/ (DNTH) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 10 insiders are actively trading DNTH stock, having executed 30 transactions in the past 90 days. The most active insider is Partners Management (gp) Llc Avidity (Executive), who has made 1 transactions totaling $18.0M.
Get notified when executives and directors at DNTH file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 3, 2026 | Garcia Marino | Executive | Award | 355,000 | $N/A | $0 | |
| Feb 3, 2026 | Savitz Ryan | EVP, CFO & CBO | Award | 150,000 | $N/A | $0 | C-Suite |
| Feb 3, 2026 | Randhawa Simrat | EVP, Head of R&D | Award | 150,000 | $N/A | $0 | |
| Feb 3, 2026 | M. Veness Adam | SVP, General Counsel and Sec. | Award | 100,000 | $N/A | $0 | |
| Feb 3, 2026 | Carr Edward | CHIEF ACCOUNTING OFFICER | Award | 55,000 | $N/A | $0 | |
| Dec 4, 2025 | Savitz Ryan | Executive | Option Exercise | 20,000 | $8.44 | $168.8K | |
| Dec 4, 2025 | Savitz Ryan | Executive | Sale | 20,000 | $45.18 | $903.6K | Large |
| Nov 14, 2025 | Randhawa Simrat | Executive | Sale | 109,031 | $38.14 | $4.2M | Large |
| Nov 14, 2025 | Randhawa Simrat | Executive | Option Exercise | 31,250 | $22.07 | $689.7K | Large |
| Nov 14, 2025 | Randhawa Simrat | Executive | Option Exercise | 37,494 | $21.77 | $816.2K | Large |
| Nov 14, 2025 | Randhawa Simrat | Executive | Option Exercise | 40,287 | $17.88 | $720.3K | Large |
| Nov 13, 2025 | Randhawa Simrat | Executive | Option Exercise | 3,529 | $17.88 | $63.1K | |
| Nov 13, 2025 | Randhawa Simrat | Executive | Option Exercise | 83,978 | $8.44 | $708.8K | Large |
| Nov 13, 2025 | Randhawa Simrat | Executive | Sale | 26,166 | $35.80 | $936.7K | Large |
| Nov 13, 2025 | Randhawa Simrat | Executive | Sale | 42,765 | $37.04 | $1.6M | Large |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Award(A) | 8 | $30.0M | 68.5% |
Sale(S) | 6 | $9.0M | 20.5% |
Exercise(M) | 7 | $3.3M | 7.6% |
Purchase(P) | 7 | $1.5M | 3.3% |
Other(J) | 2 | $0 | 0.0% |
Insider selling pressure at Dianthus Therapeutics, Inc. /DE/ has increased, with 10 insiders executing 30 transactions across all time. Total sales of $9.0M significantly outpace purchases of $1.5M, resulting in a net outflow of $7.5M. This selling activity appears largely discretionary, which may warrant closer attention from investors.